Study of Subglutinol A as a Potential Immunomodulatory Agent
Subglutinol A 作为潜在免疫调节剂的研究
基本信息
- 批准号:9226543
- 负责人:
- 金额:$ 26.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-12-09 至 2018-11-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdverse effectsAffectAffinityAnti-Inflammatory AgentsAnti-inflammatoryAreaAutoimmune DiseasesAutoimmune ProcessBiochemicalBiologicalBloodCaringCell physiologyCellular Metabolic ProcessChemicalsChronicCyclosporineCytotoxic agentDataDevelopmentDiseaseDisease remissionDiterpenesDrug TargetingEnvironmental Risk FactorEtiologyEvaluationFK506FutureGenetic Predisposition to DiseaseGoalsHealthImmuneImmune responseImmunologicsImmunosuppressive AgentsIn VitroInflammatoryInflammatory Bowel DiseasesInsulin-Dependent Diabetes MellitusInvestigationLeadMedicalMetabolicMolecular TargetMorbidity - disease rateMultiple SclerosisNatural ProductsNeurologicOutcomePathogenicityPatient-Focused OutcomesPatientsPharmaceutical PreparationsPharmacologyPopulationPositioning AttributePreparationPropertyProteomicsPyronesRegulationReportingResearchRheumatoid ArthritisRiskSafetySeriesSocial ImpactsSourceSpecificitySystemic Lupus ErythematosusT memory cellT-LymphocyteTherapeuticToxic effectTransplantationWomananalogbasecell typechronic autoimmune diseaseclinical efficacydesigneconomic impactexpectationhuman diseaseimmunoregulationinnovationinsightmortalitymultimodalitynephrotoxicitynovelpharmacophorepreclinical studypreferencepreventscaffoldtherapeutic targetyoung adult
项目摘要
PROJECT SUMMARY/ABSTRACT
Autoimmune diseases are chronic inflammatory diseases of unknown etiology that results from the
combination of genetic susceptibility, environmental factors, and immune dysregulation. There are more than
80 human diseases currently classified as autoimmune, including multiple sclerosis, inflammatory bowel
diseases, type 1 diabetes mellitus, rheumatoid arthritis, and systemic lupus erythematosus. Since they affect
up to 8% of the US population and often attack young adults, especially women, their social and economic
impact is enormous.
Immunosuppressive drugs are classical therapies to treat a wide range of autoimmune diseases.
However, the treatment of autoimmune diseases has been based on non-selective immunosuppressants or
cytotoxic drugs that in general offer a limited clinical efficacy. Even more selective immunosuppressive drugs
such as cyclosporine A and FK506 possess serious side effects, including acute neurological toxicity and
chronic nephrotoxicity. Biologicals are expensive and some patients do not respond to them adequately. Thus,
efforts must be made to identify new immunomodulatory agents that are effective through a novel mechanism
to circumvent existing side effects and more selective to reduce off-target effects.
Subglutinols A and B are α-pyrone diterpenoid natural products with a novel chemical scaffold. They
showed potent immunosuppressive activity comparable to that of cyclosporine A. We reported the first total
synthesis of subglutinols A and B and demonstrated that they show multimodal immune-suppressive effects on
activated T cells and possess a significant therapeutic window. We further revealed that subglutinols might
exert their anti-inflammatory effects by affecting T cell metabolism which has been yet to be explored as an
autoimmune disease target. All together, our data suggests that subglutinols A and B may have great potential
for safe immunosuppressive therapeutics for autoimmune diseases with a novel and unique mode of action.
The objective of this proposal is to identify the molecular target(s) of subglutinols to establish their
mode of action and to develop subglutinol-derived chemical probes to study the regulation mechanism of
immune responses through the following specific aims: (1) Identify the molecular target(s) and mode of action
of sublutinols and (2) Determine the key pharmacophores of subglutinols. If successful, such therapeutics and
drug targets are expected to be useful for the treatment of autoimmune diseases and for post-transplantation
care, thus resulting in a sustained remission of the disease and better patient outcome.
项目摘要/摘要
自身免疫性疾病是一种原因不明的慢性炎症性疾病,由
遗传易感性、环境因素和免疫失调的组合。有更多的
目前80种人类疾病被归类为自身免疫性疾病,包括多发性硬化症、炎症性肠病
疾病、1型糖尿病、类风湿性关节炎和系统性红斑狼疮。因为它们会影响
高达8%的美国人口,经常攻击年轻人,特别是女性,他们的社会和经济
影响是巨大的。
免疫抑制药物是治疗多种自身免疫性疾病的经典疗法。
然而,自身免疫性疾病的治疗一直基于非选择性免疫抑制剂或
通常提供有限临床疗效的细胞毒性药物。更具选择性的免疫抑制药物
如环孢素A和FK506具有严重的副作用,包括急性神经毒性和
慢性肾毒性。生物制品价格昂贵,一些患者对它们没有足够的反应。因此,
必须努力确定通过新的机制有效的新的免疫调节剂
以避免现有的副作用,并更有选择性地减少偏离目标的影响。
亚谷氨酸甲酯和亚谷氨酸乙酯是一种新型化学支架的α-吡喃酮二萜类天然产物。他们
显示出与环孢菌素A相当的免疫抑制活性。我们报道了第一个
亚谷氨醇A和B的合成及其多峰免疫抑制作用的研究
激活的T细胞,并拥有一个重要的治疗窗口。我们进一步揭示了亚谷氨酸醇可能
通过影响T细胞代谢发挥抗炎作用,这一点尚未作为一种
自身免疫性疾病靶点。总而言之,我们的数据表明,亚谷氨酸醇A和B可能具有巨大的潜力
为自身免疫性疾病提供安全的免疫抑制疗法,具有新颖而独特的作用模式。
这项建议的目的是确定亚谷氨酸醇的分子靶点(S),以建立其
作用机制,并开发亚谷氨醇衍生的化学探针来研究其调节机制
免疫应答通过以下特定目的:(1)确定分子靶点(S)和作用方式
以及(2)确定亚谷氨酸醇的关键药效团。如果成功,这种疗法和
药物靶点有望用于自身免疫性疾病的治疗和移植后。
护理,从而导致疾病的持续缓解和更好的患者结局。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jiyong Hong其他文献
Jiyong Hong的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jiyong Hong', 18)}}的其他基金
Molecular basis of adenosine transport and reuptake inhibition in human
人体腺苷转运和再摄取抑制的分子基础
- 批准号:
10549779 - 财政年份:2020
- 资助金额:
$ 26.49万 - 项目类别:
Molecular basis of adenosine transport and reuptake inhibition in human
人体腺苷转运和再摄取抑制的分子基础
- 批准号:
10338157 - 财政年份:2020
- 资助金额:
$ 26.49万 - 项目类别:
Molecular basis of adenosine transport and reuptake inhibition in human
人体腺苷转运和再摄取抑制的分子基础
- 批准号:
10384262 - 财政年份:2020
- 资助金额:
$ 26.49万 - 项目类别:
Targeting Rev1-mediated Translesion Synthesis for Cancer Therapy
靶向 Rev1 介导的跨损伤合成用于癌症治疗
- 批准号:
9099802 - 财政年份:2015
- 资助金额:
$ 26.49万 - 项目类别:
PKC zeta-Specific Inhibitors for Treatment of Methamphetamine Addiction
用于治疗甲基苯丙胺成瘾的 PKC zeta 特异性抑制剂
- 批准号:
7826641 - 财政年份:2009
- 资助金额:
$ 26.49万 - 项目类别:
PKC zeta-Specific Inhibitors for Treatment of Methamphetamine Addiction
用于治疗甲基苯丙胺成瘾的 PKC zeta 特异性抑制剂
- 批准号:
7641187 - 财政年份:2009
- 资助金额:
$ 26.49万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 26.49万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 26.49万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 26.49万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 26.49万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 26.49万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 26.49万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 26.49万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 26.49万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 26.49万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 26.49万 - 项目类别:
Discovery Grants Program - Individual